Dr. Morris on Lutetium 177 PSMA: “We have a lot of work to do”

We have a lot of work to do to define how to optimize the integration of this therapy into what we call ‘advanced prostate cancer’,” says Michael J. Morris, MD.

In this video, Michael J. Morris, MD, discusses what the impact of the VISION trial will be on clinical practices, which are ideas that were focused on at the 2021 Society of Urologic Oncology Annual Meeting. Morris is the section head of prostate cancer in the GU oncology service at the Memorial Sloan Kettering Cancer Center in New York, New York.